Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
Status:
Active, not recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is a multi-center phase II clinical trial of atezolizumab in combination with
bevacizumab as first line treatment for locally advanced or metastasic high-intermediate
tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial
to examine the efficacy of this combination measured by progression free survival according
to response evaluation Criteria in solid tumours (RECIST) version 1.1.